Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Finlabo SIM Spa
$10.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG Phase III Trial Shows Effectiveness Of Fat-Reducing Drug-Reuters


Friday, 1 Feb 2013 05:43am EST 

Reuters reported that Bayer AG said results of two Phase III trials showed ATX-101, an injectable drug to reduce fat deposits under the chin, was effective as a non-surgical treatment. 

Company Quote

140.41
-0.32 -0.22%
26 Dec 2014